Comparison of Safety and Efficacy of Dapagliflozin and Empagliflozin in Type 2 Diabetes Mellitus Patients in India

Overview

Journal Rev Assoc Med Bras (1992)

Specialty General Medicine

Date 2023 Aug 16

PMID 37585983

Authors

Amit Varshney

Ramakant Rawat

Affiliations

Soon will be listed here.

Citing Articles

Elevating Expectations: Vericiguat in Heart Failure with Reduced Ejection Fraction.

Patel P, Mishra A, Gawande S, Patel A, Varshney A J Pharm Bioallied Sci. 2025; 16(Suppl 4):S4010-S4012.

PMID: 39926952 PMC: 11805269. DOI: 10.4103/jpbs.jpbs_1392_24.

References

Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl U, Woerle H . Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015; 17(10):936-48. PMC: 5034797. DOI: 10.1111/dom.12503. View

Ridderstrale M, Andersen K, Zeller C, Kim G, Woerle H, Broedl U . Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014; 2(9):691-700. DOI: 10.1016/S2213-8587(14)70120-2. View

Gupta S, Shaikh S, Joshi P, Bhure S, Suvarna V . Long-Term Efficacy and Safety of Empagliflozin Monotherapy in Drug-Naïve Patients with Type 2 Diabetes in Indian Subgroup: Results from a 76-week Extension Trial of Phase III, Double-Blind, Randomized Study. Indian J Endocrinol Metab. 2017; 21(2):286-292. PMC: 5367232. DOI: 10.4103/ijem.IJEM_517_16. View

Ferrannini E, Berk A, Hantel S, Pinnetti S, Hach T, Woerle H . Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013; 36(12):4015-21. PMC: 3836134. DOI: 10.2337/dc13-0663. View

Papadopoulou E, Loutradis C, Tzatzagou G, Kotsa K, Zografou I, Minopoulou I . Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. J Hypertens. 2020; 39(4):749-758. DOI: 10.1097/HJH.0000000000002690. View

Neeland I, McGuire D, Chilton R, Crowe S, Lund S, Woerle H . Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016; 13(2):119-26. PMC: 4768401. DOI: 10.1177/1479164115616901. View

Plodkowski R, McGarvey M, Huribal H, Reisinger-Kindle K, Kramer B, Solomon M . SGLT2 Inhibitors for Type 2 Diabetes Mellitus Treatment. Fed Pract. 2019; 32(Suppl 11):8S-15S. PMC: 6375399. View

Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde A . Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012; 97(3):1020-31. DOI: 10.1210/jc.2011-2260. View

Kario K, Ferdinand K, OKeefe J . Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. Prog Cardiovasc Dis. 2020; 63(3):249-262. DOI: 10.1016/j.pcad.2020.04.003. View

10.

Ferrannini E, Ramos S, Salsali A, Tang W, List J . Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010; 33(10):2217-24. PMC: 2945163. DOI: 10.2337/dc10-0612. View

11.

Viswanathan V, Singh K . Use of Dapagliflozin in the Management of Type 2 Diabetes Mellitus: A Real-World Evidence Study in Indian Patients (FOREFRONT). Diabetes Technol Ther. 2019; 21(8):415-422. DOI: 10.1089/dia.2019.0052. View

12.

Ji L, Ma J, Li H, Mansfield T, Tjoen C, Iqbal N . Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther. 2014; 36(1):84-100.e9. DOI: 10.1016/j.clinthera.2013.11.002. View

13.

Nauck M, Del Prato S, Meier J, Duran-Garcia S, Rohwedder K, Elze M . Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011; 34(9):2015-22. PMC: 3161265. DOI: 10.2337/dc11-0606. View

14.

Kalra S . Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology. Diabetes Ther. 2014; 5(2):355-66. PMC: 4269649. DOI: 10.1007/s13300-014-0089-4. View

15.

Anjana R, Pradeepa R, Deepa M, Datta M, Sudha V, Unnikrishnan R . The Indian Council of Medical Research-India Diabetes (ICMR-INDIAB) study: methodological details. J Diabetes Sci Technol. 2011; 5(4):906-14. PMC: 3192597. DOI: 10.1177/193229681100500413. View

16.

Hussain M, Elahi A, Iqbal J, Ghafoor M, Rehman H, Akhtar S . Comparison of Efficacy and Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy in Patients With Type 2 Diabetes. Cureus. 2021; 13(4):e14268. PMC: 8090899. DOI: 10.7759/cureus.14268. View

17.

Bailey C, Gross J, Hennicken D, Iqbal N, Mansfield T, List J . Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013; 11:43. PMC: 3606470. DOI: 10.1186/1741-7015-11-43. View

18.

Pereira M, Eriksson J . Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. Drugs. 2019; 79(3):219-230. PMC: 6394798. DOI: 10.1007/s40265-019-1057-0. View